Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mustang Bio Inc MBIO

Healthcare Biotechnology
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene... see more

Recent & Breaking News (NDAQ:MBIO)

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

GlobeNewswire May 18, 2023

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire May 15, 2023

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire May 12, 2023

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

GlobeNewswire May 11, 2023

Mustang Bio Announces Reverse Stock Split

GlobeNewswire April 3, 2023

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire March 30, 2023

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire March 29, 2023

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

GlobeNewswire March 28, 2023

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

GlobeNewswire January 17, 2023

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

GlobeNewswire December 19, 2022

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire November 14, 2022

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

GlobeNewswire October 27, 2022

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

GlobeNewswire October 6, 2022

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

GlobeNewswire September 8, 2022

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire August 11, 2022

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

GlobeNewswire July 27, 2022

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

GlobeNewswire June 22, 2022

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

GlobeNewswire June 13, 2022

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

GlobeNewswire May 19, 2022

Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire May 12, 2022